ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the High growth stocks to invest in now. On October 13, Barclays’ Etzer Darout initiated ABIVAX Société Anonyme (NASDAQ:ABVX) with an Overweight rating and a $142 price target.
Analysts noted that they began coverage of eight companies in the inflammation, immunology, oncology and rare disease sectors. He explained that while investing in small- and mid-cap biotech stocks has binary risks. However, investments based on prior clinical data and other de-risking mechanisms present a favorable risk/reward situation that has significant advantages.
Additionally, the firm also believes that the market is currently rewarding new mechanisms and treatments that have the potential to improve dosing and compliance.
In addition to Barclays, on October 10, Guggenheim’s Yatin Suneja reiterated a Buy rating on ABIVAX Société Anonyme (NASDAQ:ABVX) with a $150 price target.
ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company developing antiviral compounds and therapeutic vaccines for serious infectious diseases.
While we recognize the potential of ABVX as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.